Nasdaq

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- ...
Nasdaq

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services ( ...
Seeking Alpha

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, ...
Becker's ASC

Drug Code Changes Included in July HCPCS Level II Updates

The July 1 quarterly HCPCS Level II update includes several drug/biological code changes, according to an AAPC release. Effective July 1, the HCPCS Level II code J7184 will be replaced with Q2041 ...
JD Supra

New HCPCS for Advanced Primary Care Management

The Center for Medicare & Medicaid Services (CMS) issued the display copy of the final Calendar Year 2025 Physician Fee Schedule on November 1, 2024, which included three new Healthcare Common ...
Seeking Alpha

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and ...